A Role for Anabolic Steroids in the Rehabilitation of Patients with COPD? A Double-Blind, Placebo-Controlled, Randomized Trial

Chest

Volumn 124, Issue 5, 2003, Pages 1733-1742

  Creutzberg, Eva C ^a   Wouters, Emiel F M ^a   Mostert, Rob ^b   Pluymers, Rob J ^c   Schols, Annemie M W J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Asthma Center Hornerheide   (Netherlands)

^c NV ORGANON   (Netherlands)

Author keywords

Anabolic steroids; Body composition; COPD; Erythropoietin; Exercise capacity; Health status; Muscle function; Nandrolone decanoate; Oral glucocorticosteroids; Testosterone

Indexed keywords

ANABOLIC AGENT; ARACHIS OIL; BROMIDE; DEUTERIUM; ERYTHROPOIETIN; GLUCOCORTICOID; HEMOGLOBIN; NANDROLONE DECANOATE;

AGED; ARTICLE; BODY COMPOSITION; BREATHING MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXERCISE TEST; HEALTH PROGRAM; HEALTH STATUS; HUMAN; ISOKINETIC EXERCISE; LEG EXERCISE; MAJOR CLINICAL STUDY; MALE; MUSCLE FUNCTION; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REHABILITATION; SIDE EFFECT; STANDARDIZATION; TREATMENT OUTCOME; WORKLOAD;

EID: 0242721245     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.5.1733     Document Type: Article

References (45)

1. Meek PM, Schwartzstein RM, Adams L, et al. Dyspnea: mechanisms, assessment, and management; a consensus statement. Am J Respir Crit Care Med 1999; 159:321-340
2. Hamilton AL, Killian KJ, Summers E, et al. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995; 152:2021-2031
3. Engelen MPKJ, Schols AMWJ, Baken WC, et al. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J 1994; 7:1793-1797
4. Schols AMWJ, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147:1151-1156
5. Kamischke A, Kemper DE, Castel MA, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J 1998; 11: 41-45
6. Decramer M, Lacquet LM, Fagard R, et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150:11-16
7. Bernard S, LeBlanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:629-634
8. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary Am J Respir Crit Care Med 2001; 163:1256-1276
9. Schols AMWJ, Soeters PB, Mostert R, et al. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: a placebo-controlled randomized trial. Am J Respir Crit Care Med 1995; 152:1268-1274
10. Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114:19-28
11. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiological doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335:1-7
12. Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992; 37:264-267
13. van Balkom RHH, Dekhuijzen PNR, Folgering HTM, et al. Anabolic steroids in part reverse glucocorticoid-induced alterations in rat diaphragm. J Appl Physiol 1998; 84:1492-1499
14. van Balkom RH, Dekhuijzen PN, van der Heijden HF, et al. Effects of anabolic steroids on diaphragm impairment induced by methylprednisolone in emphysematous hamsters. Eur Respir J 1999; 13:1062-1069
15. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:S77-S121
16. Quanjer PH. Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J 1993; 6(suppl 16):1-100
17. Westerterp KR, Wouters L, van Marken Lichtenbelt WD. The Maastricht protocol for the measurement of body composition and energy expenditure with labeled water. Obes Res 1995; 3(Suppl 1):49-57
18. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 1969; 99:696-702
19. Jones NL. Clinical exercise testing. Philadelphia, PA: Saunders, 1988; 158-185
20. Maltais F, Jobin J, Sullivan MJ, et al. Metabolic and hemodynamic responses of lower limb during exercise in patients with COPD. J Appl Physiol 1998; 84:1573-1580
21. Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995; 107:187S-193S
22. Bijlsma JW, Duursma SA, Thijssen JH, et al. Influence of nandrolone decanoate on the pituitary-gonadal axis in males. Acta Endocrinol (Copenh) 1982; 101:108-112
23. Swinkels LM, Ross HA, Benraad TJ. A symmetric dialysis method for the determination of free testosterone in human plasma. Clin Chim Acta 1987; 165:341-349
24. Swinkels LM, Meulenberg PM, Ross HA, et al. Salivary and plasma free testosterone and androstenedione levels in women using oral contraceptives containing desogestrel or levonorgestrel. Ann Clin Biochem 1988; 25:354-359
25. Sauerwein HP, Romijn JA. More consideration to dietary protein in the nutrition of chronically ill adults with tendency to weight loss [in Dutch]. Ned Tijdschr Geneeskd 1999; 143:886-889
26. Altman DG, Gore SM, Gardner MJ, et al. Statistical guidelines for contributors to medical journals. BMJ (Clin Res Ed) 1983; 286:1489-1493
27. Bhasin S, Bagatell CJ, Bremner WJ, et al. Therapeutic perspective: issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998; 83:3435-3448
28. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab 1996; 81:3469-3475
29. Kuipers H, Peeze Binkhorst FM, Hartgens F, et al. Muscle ultrastructure after strength training with placebo or anabolic steroid. Can J Appl Physiol 1993; 18:189-196
30. Bartsch W. Anabolic steroids: action on cellular level. Wien Med Wochenschr 1993; 143:363-366
31. Ferrando AA, Tipton KD, Doyle D, et al. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol 1998; 275:E864-E871
32. Sheffield-Moore M, Wolfe RR, Gore DC, et al. Combined effects of hyperaminoacidemia and oxandrolone on skeletal muscle protein synthesis. Am J Physiol Endocrinol Metab 2000; 278:E273-E279
33. Hartgens F. Androgenic-anabolic steroid use in strength athletes; effects on body composition and cardiovascular system [doctoral thesis]. Maastricht, The Netherlands: University Hospital Maastricht, 2001
34. Maltais F, LeBlanc P, Simard C, et al. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154:442-447
35. Tsukino M, Nishimura K, Ikeda A, et al. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998; 53:269-273
36. Ballal SH, Domoto DT, Polack DC, et al. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17:29-33
37. Solomon LR, Hendler ED. Androgen therapy in haemodialysis patients: II. Effects on red cell metabolism Br J Haematol 1987; 65:223-230
38. Simelaro JP, Venditto M, Ghen MJ, et al. Effect of erythrocytes of androgens on 2, 3-diphosphoglycerate in patients with chronic obstructive pulmonary disease. J Am Osteopath Assoc 1980; 79:388-390
39. Berry MJ, Rejeski WJ, Adair NE, et al. Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med 1999; 160:1248-1253
40. Bernard S, Whittom F, LeBlanc P, et al. Aerobic and strength training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:896-901
41. Hajiro T, Nishimura K, Tsukino M, et al. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest 1999; 116:1632-1637
42. O'Donnell D, Webb KA. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. Am Rev Respir Dis 1993; 148:1351-1357
43. Creutzberg EC, Schols AMWJ. Anabolic steroids. Curr Opin Clin Nutr Metab Care 1999; 2:243-253
44. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther 1997; 19:383-404
45. Drinka PJ, Jochen AL, Cuisinier M, et al. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc 1995; 43:899-901